Savior LLC’s Sage Therapeutics SAGE Stock Holding History

Savior LLC’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-32	Closed	-$1K	–	858
2020 Q1	$1K	Hold	32	–	–	﹤0.01%	748
2019 Q4	$2K	Buy	+32	New	+$3.94K	﹤0.01%	773

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Savior LLC's SAGE Position: Q2 2020 in Review

Savior LLC sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 32 shares — an estimated $1K sold.

Savior LLC first reported a position in SAGE in Q4 2019 and held it in 2 quarters. The position peaked at $2K in Q4 2019. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

Savior LLC reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
Savior LLC sold 32 Sage Therapeutics shares in Q2 2020, an estimated $1K.
Savior LLC first reported a position in Sage Therapeutics in Q4 2019 and held it in 2 quarters.
Savior LLC's Sage Therapeutics position peaked at $2K in Q4 2019.
217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on Savior LLC's 13F filing for Q2 2020, filed 28 Jul 2020.